Oblique Therapeutics > News > News > Oblique Therapeutics AB together with collaborators at Sahlgrenska University Hospital (Gothenburg) and Karolinska Institutet (Stockholm) has been granted 5MSEK by Vinnova to develop neutralizing antibodies towards SARS-CoV-2 and to develop its Abiprot platform into a first-line-of-defence for future pandemics.
Archive
Categories
08 Oct 2020

Oblique Therapeutics AB together with collaborators at Sahlgrenska University Hospital (Gothenburg) and Karolinska Institutet (Stockholm) has been granted 5MSEK by Vinnova to develop neutralizing antibodies towards SARS-CoV-2 and to develop its Abiprot platform into a first-line-of-defence for future pandemics.

You can read our English Press Release, clicking here:

Oblique Therapeutics together with collaborators at Sahlgrenska University Hospital and Karolinska Institutet has been granted 5MSEK by Vinnova.